Doç. Dr. Deniz Işık

Prognostic Impact and Clinicopathological Correlates of HER2 Status in Gastric Cancer: A Multicenter Retrospective Turkish Oncology Group Study

Clinical Medicine Insights Oncology, 2026

DOI 10.1177/11795549261445290 PMID 42131419 Texte intégral en libre accèsSource : OpenAlex

Nutritional Indexes and Their Variations as Predictors of Atezolizumab Plus Chemotherapy Efficacy in Extensive-Stage Small Cell Lung Cancer: A Turkish Oncology Group Study

Journal of Immunotherapy, 2026

DOI 10.1097/cji.0000000000000610 PMID 42267536 Source : OpenAlex

Prognostic value of PSA Kinetic Ratio in high-volume mCSPC patients treated with abiraterone or enzalutamide: a single-center retrospective study

BMC Cancer, 2026

DOI 10.1186/s12885-026-16037-8 PMID 41987096 Texte intégral en libre accèsSource : OpenAlex

Association Between Time to PSA Nadir, Radiologic Progression, and PSA Progression in mHSPC Patients Treated with Abiraterone or Enzalutamide

Journal of Clinical Medicine, 2026

DOI 10.3390/jcm15010386 PMID 41517635 1 citation (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Association between GRIm score and response to nivolumab monotherapy in patients with advanced malignant melanoma

Journal of Cancer Research and Clinical Oncology, 2026

DOI 10.1007/s00432-025-06411-7 PMID 41504775 3 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Impact of Peri-Immunotherapy Antibiotic Exposure on Survival Outcomes in Metastatic Renal Cell Carcinoma: A Real-World IMDC Risk–Stratified Analysis

Journal of Clinical Medicine, 2026

DOI 10.3390/jcm15051853 PMID 41827267 1 citation (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Significance of CEA Dynamics and Systemic Inflammatory Markers in HER2-Positive Metastatic Colorectal Cancer Patients Undergoing First-Line Chemotherapy: A Real-World Cohort Study

Medicina, 2026

DOI 10.3390/medicina62010099 PMID 41597386 1 citation (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Adjuvant Chemotherapy and Chemoradiotherapy in Gastric Cancer: Prognostic Determinants and Real-World Survival Outcomes

Journal of Clinical Medicine, 2026

DOI 10.3390/jcm15020553 PMID 41598493 Texte intégral en libre accèsSource : OpenAlex

Clinical Outcomes of Stage IS Non-seminomatous Germ Cell Testicular Tumors: Single-Center Experience

Istanbul Medical Journal, 2026

DOI 10.4274/imj.galenos.2026.62829 Texte intégral en libre accèsSource : OpenAlex

Association Between Body Mass Index and Clinical Outcomes of CDK4/6 Inhibitors in HR+/HER2− Metastatic Breast Cancer: A Real-World Cohort Study

Journal of Clinical Medicine, 2026

DOI 10.3390/jcm15041671 PMID 41753358 Texte intégral en libre accèsSource : OpenAlex

657eP Time toxicity of CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer: A real-world comparative study of palbociclib and ribociclib

ESMO Open, 2026

DOI 10.1016/j.esmoop.2026.107673 Source : OpenAlex

Prognostic Significance of Preoperative PET-CT SUVmax in Resected Non-Small Cell Lung Cancer: A Single-Center Retrospective Study

Medicina, 2026

DOI 10.3390/medicina62061004 PMID 42356017 Texte intégral en libre accèsSource : OpenAlex

FOLFOX Plus Bevacizumab Rechallenge Versus Regorafenib as Third-Line Treatment in Metastatic Colorectal Cancer: The Role of the Oxaliplatin-Free Interval

Cancers, 2026

DOI 10.3390/cancers18182987 PMID 42794953 Texte intégral en libre accèsSource : OpenAlex

Prognostic Factors and Survival in Thymoma and Thymic Carcinoma: A Retrospective Cohort Study

Cerrahpasa Medical Journal, 2026

DOI 10.5152/cjm.2026.26089 Texte intégral en libre accèsSource : OpenAlex

Real-life data on adjuvant trastuzumab emtansine treatment in early-stage HER2-positive breast cancer: a Turkish Oncology Group study

Anti-Cancer Drugs, 2025

DOI 10.1097/cad.0000000000001717 PMID 40162996 1 citation (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

The Association of Khorana Risk Score with Venous Thromboembolism and Overall Survival in Patients with Metastatic Gastric Cancer

Medicina, 2025

DOI 10.3390/medicina61061075 PMID 40572762 6 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Efficacy and Clinical Outcomes of Crizotinib in Patients with ROS1-Rearranged NSCLC: A Multicenter Study

Medicina, 2025

DOI 10.3390/medicina61030490 PMID 40142301 2 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study

Clinical Breast Cancer, 2025

DOI 10.1016/j.clbc.2025.03.003 PMID 40190010 2 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

HER2-low expression in patients with hormone receptor positive and HER2 negative advanced breast cancer treated with ribociclib or palbociclib in combination with endocrine therapy

Turkish Journal of Clinics and Laboratory, 2025

DOI 10.18663/tjcl.1639022 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

Tumor-infiltrating lymphocytes as predictive biomarkers in neoadjuvant treatment of HER2-positive breast cancer

The Oncologist, 2025

DOI 10.1093/oncolo/oyaf054 PMID 40271640 5 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Evaluating the Performance of ChatGPT-4o Oncology Expert in Comparison to Standard Medical Oncology Knowledge: A Focus on Treatment-Related Clinical Questions

Cureus, 2025

DOI 10.7759/cureus.78076 PMID 39872919 2 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Triple-Negative Apocrine Carcinoma: Largest Cohort Highlights Unique Biology and Survival Advantage

Journal of Clinical Medicine, 2025

DOI 10.3390/jcm14197103 PMID 41096183 4 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Development of a Machine Learning-Based Prognostic Model Using Systemic Inflammation Markers in Patients Receiving Nivolumab Immunotherapy: A Real-World Cohort Study

Journal of Personalized Medicine, 2025

DOI 10.3390/jpm16010008 PMID 41590501 3 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

The Effect of the Clinical-Pathological CPS+EG Staging System on Survival Outcomes in Patients with HER2-Positive Breast Cancer Receiving Neoadjuvant Treatment: A Retrospective Study

Medicina, 2025

DOI 10.3390/medicina61101813 PMID 41155800 1 citation (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Prognostic Impact of Tumor Size in Patients with Stage T3N1 Colon Cancer

Journal of Clinical Medicine, 2025

DOI 10.3390/jcm15010247 PMID 41517497 Texte intégral en libre accèsSource : OpenAlex

Comparison of paclitaxel and docetaxel in dual HER2 blockade: efficacy and safety in neoadjuvant treatment of HER2-positive breast cancer

Breast Cancer Research and Treatment, 2025

DOI 10.1007/s10549-025-07694-7 PMID 40214840 2 citations (Europe PMC) Source : OpenAlex

Impact of HER2 Status Assessed by Immunohistochemistry on Treatment Response in Patients with Metastatic Breast Cancer Receiving Trastuzumab Emtansine

Medicina, 2025

DOI 10.3390/medicina61050819 PMID 40428777 1 citation (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Effects of Metformin on Survival and Toxicity in Patients with Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab

Medicina, 2025

DOI 10.3390/medicina61071161 PMID 40731791 1 citation (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

The impact of carboplatin on pathologic complete response and survival based on HER2 low and HER2 zero status in triple negative breast cancer patients receiving neoadjuvant chemotherapy: a multicenter real-world analysis

BMC Cancer, 2025

DOI 10.1186/s12885-025-14252-3 PMID 40329228 3 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Impact of Age and Menopausal Status on T-DM1 (Ado-Trastuzumab Emtansine) Treatment Outcomes in HER2-Positive Breast Cancer

Pharmaceuticals, 2025

DOI 10.3390/ph18060931 PMID 40573326 1 citation (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Single-Center Real World Study of Everolimus and Exemestane in HR+/HER2− Metastatic Breast Cancer Following CDK4/6 Inhibitor Therapy

Current Oncology, 2025

DOI 10.3390/curroncol32090503 PMID 41002573 1 citation (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Impact of Metastasectomy on Survival Outcomes in Colorectal Cancer: A Single Center Retrospective Study

Acta haematologica oncologica Turcica., 2025

DOI 10.4274/ahot.galenos.2025.2025-1-1 Texte intégral en libre accèsSource : OpenAlex

Very Favorable vs. Favorable Risk Groups in Metastatic Renal Cell Carcinoma: A Step Toward Personalized Treatment

Cancers, 2025

DOI 10.3390/cancers17071076 PMID 40227569 Texte intégral en libre accèsSource : OpenAlex

Effect of Family and Personal Medical History on Treatment Outcomes of Tyrosine Kinase Inhibitors (TKIs) in Non-Small Cell Lung Cancer (NSCLC)

Healthcare, 2025

DOI 10.3390/healthcare13151810 PMID 40805843 Texte intégral en libre accèsSource : OpenAlex

Association Between Prognostic Nutritional Index and Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors

Cerrahpasa Medical Journal, 2025

DOI 10.5152/cjm.2025.25030 Texte intégral en libre accèsSource : OpenAlex

The efficacy of targeted therapies in metastatic squamous cell carcinoma of the lung: a Turkish Oncology Group multicentre study

Journal of Chemotherapy, 2025

DOI 10.1080/1120009x.2025.2601938 PMID 41414901 Source : OpenAlex

Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases

Scientific Reports, 2024

DOI 10.1038/s41598-024-56046-w PMID 38461209 16 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective study

BMC Cancer, 2024

DOI 10.1186/s12885-024-13357-5 PMID 39736618 4 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

The role of laboratory indices on treatment response and survival in breast cancer receiving neoadjuvant chemotherapy

Scientific Reports, 2024

DOI 10.1038/s41598-024-63096-7 PMID 38802494 21 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Prognostic Impact and Clinical Features of Spread through Air Spaces in Operated Lung Cancer: Real-World Analysis

Medicina, 2024

DOI 10.3390/medicina60081374 PMID 39202654 10 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Neoadjuvant Chemotherapy and Pathologic Complete Response in HR+/HER2− Breast Cancer: Impact of Tumor Ki67 and ER Status

Chemotherapy, 2024

DOI 10.1159/000537874 PMID 38368871 5 citations (Europe PMC) Source : OpenAlex

A Novel Prognostic Indicator for Immunotherapy Response: Lymphocyte-to-Albumin (LA) Ratio Predicts Survival in Metastatic NSCLC Patients

Cancers, 2024

DOI 10.3390/cancers16142512 PMID 39061152 5 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Evaluating the Effectiveness of Nivolumab in Metastatic Lung Cancer Among Patients Aged 65 and Older

Journal of Clinical Medicine, 2024

DOI 10.3390/jcm13206263 PMID 39458213 2 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Does Adjuvant Chemotherapy Benefit Patients with T4 N0 Colon Cancer?

Medicina, 2024

DOI 10.3390/medicina60081372 PMID 39202652 3 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Clinical Effectiveness of Targeted Therapies Following Nivolumab Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-World Study

Medicina, 2024

DOI 10.3390/medicina60071088 PMID 39064516 1 citation (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Trastuzumab Rechallenge in HER2-Positive Metastatic Breast Cancer: A Promising Strategy for Enhanced Progression-Free Survival Post Ado-Trastuzumab Emtansine Progression

Medicina, 2024

DOI 10.3390/medicina60122069 PMID 39768949 2 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Exploring the Clinical Impact of RANK Pathway Inhibition in Advanced Breast Cancer: Insights From a Retrospective Study on CDK4/6 Inhibitors and Antiresorptive Therapy

Cureus, 2024

DOI 10.7759/cureus.63362 PMID 39070363 1 citation (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Combining Endocrine Therapy with Trastuzumab Emtansine Improves Progression-Free Survival and Overall Survival in HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer

Medicina, 2024

DOI 10.3390/medicina60060951 PMID 38929568 1 citation (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

A propensity score‐matched comparison of neoadjuvant chemoradiotherapy with cisplatin‐ 5FU and carboplatin–paclitaxel in locally advanced esophageal squamous cell carcinoma: A Turkish oncology group study

Cancer Medicine, 2024

DOI 10.1002/cam4.70002 PMID 39030808 1 citation (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Male breast cancer in a single-center experience: Diagnosis, clinicopathological features, and treatment strategies

Northern Clinics of Istanbul, 2024

DOI 10.14744/nci.2024.32815 PMID 39431041 Texte intégral en libre accèsSource : OpenAlex